Clinical research jobs provider GlaxoSmithKline (GSK) has announced that it will collaborate with Alnylam Pharmaceuticals through an integration of the company's VaxiRNATM technology into vaccines for influenza.
The UK pharmaceutical giant will aim to apply the platform to its existing cell culture production processes for making shots for influenza and other pathogens, according to a statement from Alynlam.
VaxiRNATM is a new RNA interference technology for the enhanced production of viruses utilised during vaccine manufacture.
John Maraganore, Alynlam chief executive, said: "We are excited to form a new collaboration with GSK, a global leader and innovator in vaccine development and manufacturing."
As part of the agreement, GSK is set to provide funding and milestone payments to Alynlam, which will also result in the payment of royalties to the company if a commercial product is released.
Alynlam recently reported its financial results for the third quarter of 2011, which showed revenues of $20.8 million (£12.9 million), compared with $27.7 million for the same period of 2010.